What Brookdale’s latest guidance means for investors

Brookdale Senior Living (BKD) recently reaffirmed its 2026 outlook, pairing its first quarter earnings release with an update on RevPAR expectations, adjusted EBITDA targets, occupancy trends, and portfolio reshaping efforts.

The company reported first quarter sales of US$722.46 million and revenue of US$764.86 million, with a net loss of US$6.89 million. That compares with sales of US$777.45 million, revenue of US$813.86 million, and a net loss of US$64.98 million a year earlier.

Loss per share from continuing operations came in at US$0.03 on both a basic and diluted basis, compared with US$0.28 a year ago. Alongside these numbers, management highlighted RevPAR growth guidance of 8% to 9% for 2026 and adjusted EBITDA expectations of US$502 million to US$516 million, supported by improving occupancy and an operations-focused model.

Brookdale’s reaffirmed 2026 guidance comes after a sharp move over the past year, with the share price still up 19.74% year to date despite a 20.32% decline over the past three months and a very large 1 year total shareholder return of 89.77%. This reflects how quickly sentiment has shifted as investors reassess both growth potential and risk around the company’s pivot to an operations focused model and ongoing community dispositions.

If Brookdale’s repositioning has your attention, it can be useful to see how other healthcare related operators are priced and growing, starting with 34 healthcare AI stocks

With Brookdale’s share price up strongly over 1 year yet down over the past quarter, plus an indicated intrinsic discount and a large gap to analyst targets, the key question is simple: is there still a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 23.6% Undervalued

Brookdale’s most followed narrative points to a fair value of $17.00 per share versus the last close at $12.98. This frames the recent guidance within a discounted valuation built on detailed earnings and margin assumptions.

Brookdale's accelerating occupancy rates, now consistently above the critical 80 percent threshold, have led to robust free cash flow generation and rising adjusted EBITDA, signaling that core revenue and earnings power are on an improving long-term trajectory.

The company has effective portfolio optimization by shedding underperforming assets and focusing on high-potential communities, which is expected to increase occupancy rates, revenue per occupied room, adjusted EBITDA, and overall net margins over time.

Curious what has to happen for that $17.00 fair value to stack up? The narrative leans on a sharp earnings swing, steadier revenue growth, and a future earnings multiple that assumes investors will pay up for a cleaner, more profitable business model.

Result: Fair Value of $17.00 (UNDERVALUED)

However, this upside view depends on occupancy, Health Plus uptake, and capital projects staying on track, with higher labor or compliance costs still capable of squeezing margins.

Next Steps

Seeing both risks and rewards in this story so far? You may wish to move quickly, review the underlying data for yourself, and weigh up 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Brookdale has sparked your interest, do not stop here. The next moves in your portfolio could come from stocks you have not even considered yet.

• Target potential mispricing and see which companies screen as high quality yet out of favor by checking the 49 high quality undervalued stocks.
• Strengthen your income stream and compare companies offering higher yields and resilient payouts using the 12 dividend fortresses.
• Prioritize resilience and stress test your watchlist against companies with steadier profiles through the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.